haematology
Blood cancers

Building a bridge to transplant in hard-to-treat leukaemia

Sponsored by Pfizer Australia

There has been a dichotomy between what we have and what we want for patients with B-cell acute lymphoblastic leukaemia (ALL). What we want is a cure for many, but in reality current standard of care chemotherapy regimens only offer a cure for some. Although 80-90% of patients who are newly diagnosed may achieve complete ...

Already a member?

Enter your email to keep reading.


OR